Sarepta Therapeutics (SRPT) Operating Margin (2012 - 2026)
Sarepta Therapeutics' quarterly Operating Margin came in at 89.54% in Q1 2026, up 31483.0% year-on-year from N/an in Q1 2025, and up 196.36% quarter-over-quarter from 92.92% in Q4 2025.
Sarepta Therapeutics has reported Operating Margin for 13 years, with the latest figure at 89.54% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 31483.0% year-over-year to 89.54%; the trailing twelve-month figure through Mar 2026 stood at 2.21% (up 502.0% YoY), and the FY2025 full-year result was 31.83%, down 4330.0% from the prior year.
- Operating Margin for Q1 2026 stood at 89.54%, up from 92.92% in the prior quarter.
- The five-year high for Operating Margin was 89.54% in Q1 2026, with the low at 600.09% in Q2 2023.
- Average Operating Margin over 5 years is 86.75%, with a median of 25.89% recorded in 2025.
- Year-over-year, Operating Margin sank 50012 bps in 2023 and jumped 59989 bps in 2024.
- Tracing SRPT's Operating Margin over 5 years: stood at 63.15% in 2022, then soared by 108 bps to 5.31% in 2023, then jumped by 362 bps to 24.56% in 2024, then plunged by 478 bps to 92.92% in 2025, then jumped by 196 bps to 89.54% in 2026.
- The last three Operating Margin figures came in at 89.54% (Q1 2026), 92.92% (Q4 2025), and 25.89% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 89.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.54% |
| Dec 31, 2025 | -92.92% |
| Sep 30, 2025 | -25.89% |
| Jun 30, 2025 | 18.91% |
| Mar 31, 2025 | -225.29% |
| Dec 31, 2024 | 24.56% |
| Sep 30, 2024 | 4.75% |
| Jun 30, 2024 | -0.19% |
| Mar 31, 2024 | 8.44% |
| Dec 31, 2023 | 5.31% |
| Sep 30, 2023 | -6.28% |
| Jun 30, 2023 | -600.09% |
| Mar 31, 2023 | -54.47% |
| Dec 31, 2022 | -63.15% |
| Sep 30, 2022 | -63.22% |
| Jun 30, 2022 | -99.97% |
| Mar 31, 2022 | -394.82% |
| Dec 31, 2021 | -94.50% |
| Sep 30, 2021 | -18.19% |
| Jun 30, 2021 | -118.14% |
| Mar 31, 2021 | -103.36% |
| Dec 31, 2020 | -758.94% |
| Sep 30, 2020 | -609.33% |
| Jun 30, 2020 | -531.74% |
| Mar 31, 2020 | -892.38% |
| Dec 31, 2019 | -229.96% |
| Sep 30, 2019 | -124.79% |
| Jun 30, 2019 | -290.88% |
| Mar 31, 2019 | -87.79% |
| Dec 31, 2018 | -165.09% |
| Sep 30, 2018 | -89.31% |
| Jun 30, 2018 | -140.66% |
| Mar 31, 2018 | -47.58% |
| Dec 31, 2017 | -40.41% |
| Sep 30, 2017 | -99.90% |
| Jun 30, 2017 | -180.91% |
| Mar 31, 2017 | -240.15% |
| Dec 31, 2014 | -165,637.04% |
| Sep 30, 2014 | -3,179.89% |
| Jun 30, 2014 | -1,171.93% |
| Mar 31, 2014 | -412.63% |
| Dec 31, 2013 | -1,250.91% |
| Sep 30, 2013 | -598.20% |
| Jun 30, 2013 | -579.02% |
| Mar 31, 2013 | -344.55% |
| Dec 31, 2012 | -141.30% |
| Sep 30, 2012 | -91.17% |
| Jun 30, 2012 | -49.59% |
| Mar 31, 2012 | -61.31% |